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Abstract:  
Assessment of left ventricular (LV) volumes and ejection fraction (LVEF) with cardiac 
imaging is important in the selection of patients for cardiac resynchronization therapy 
(CRT). Several observational studies have explored the role of imaging-derived LV 
dyssynchrony parameters to predict the response to CRT, but have yielded inconsistent 
results, precluding the inclusion of imaging-derived LV dyssynchrony parameters in 
current guidelines for selection of patients for CRT. The EuroCRT is a large European 
multicentre prospective observational study led by the European Association of 
Cardiovascular Imaging (EACVI). We aim to explore if combing the value of Cardiac 
magnetic resonance (CMR) and echocardiography could be beneficial for selecting heart 
failure patients for CRT in terms of improvement in long-term survival, clinical symptoms, 
LV function and volumes. Speckle tracking echocardiography will be used to assess LV 
dyssynchrony and wasted cardiac work whereas myocardial scar will be assessed with 
late gadolinium contrast enhanced CMR. All data will be measured in core laboratories. 
The study will be conducted in European centres with known expertise in both CRT and 
multimodality cardiac imaging.  
Keywords: cardiac resynchronization therapy, cardiac magnetic 
resonance,echocardiography, strain, observational study. 
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Introduction 
The potential role of cardiac imaging to identify which patients with heart failure benefit 
from cardiac resynchronization therapy (CRT) has been assessed in several studies (1-
6). Echocardiography is used to assess left ventricular ejection fraction (LVEF) and 
volumes according to current guidelines, but echocardiographic measures of cardiac 
dyssynchrony were considered not sufficiently validated and robust to be implemented in 
the current guidelines (7). Echocardiographic parameters have mostly been tested in 
single-centre studies with small cohorts and often in retrospective studies (8-10). The 
prospective observational PROSPECT trial showed that the initially proposed 
echocardiographic parameters of cardiac dyssynchrony had a modest accuracy to predict 
response to CRT (8). Subsequent studies have shown that speckle tracking 
echocardiography may be a better tool to reliably measure LV dyssynchrony (1, 11-13).  
In the normal heart, all LV segments contract in a relatively synchronized fashion and 
contribute to blood ejection into the aorta. When there is electrical conduction delay, 
however, early and late activated segments contract at different times and energy might 
be wasted in stretching opposing segments (12, 14-16). As observed typically in patients 
with left bundle branch block (LBBB), the early-activated septum contracts prior to aortic 
valve opening and stretches the LV lateral wall, and contraction in the late activated lateral 
wall causes a variable degree of systolic lengthening of the septum(1, 17, 18). The 
negative work during systolic lengthening makes no contribution to LV ejection, and 
therefore represents a waste. It has been suggested that the amount of effective 
(positive) work remaining in the dyssynchronous ventricle reflects the potential for 
recovery of function after CRT (15, 16, 19). LV pressure-strain loops (PSLs) are a novel 
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and reliable tool for the non-invasive assessment of myocardial work (15, 16, 20). 
Furthermore, the use of cardiovascular magnetic resonance (CMR) in particular with late 
gadolinium enhancement (LGE), permits the assessment of myocardial scar which has 
been associated with poor response to CRT (21-23). The combination of LV dyssynchrony 
assessment with speckle tracking echocardiography and myocardial scar assessment 
with CMR has shown better accuracy to identify patients who will benefit from CRT (21, 
24, 25). However, these single-center studies included only small cohorts of patients and 
dyssynchrony was not extensively evaluated.  
Therefore, we propose an European international observational study (EuroCRT) to 
determine the role of multimodality imaging to identify heart failure patients who will 
benefit from CRT. The objectives of the present study are as follows: 
 To explore the combined value of LV mechanical dyssynchrony and wasted 
cardiac work measured with speckle tracking echocardiography and of 
myocardial scar measured with LGE-CMR to accurately identify patients who will 
benefit from CRT. 
 To test the robustness of this combined approach.  
The results of this observational study will constitute a step forward to proposing a new 
prospective randomized study. 
 
Methods 
The EuroCRT survey will be conducted in high volume centres with specific expertise in 
the evaluation and treatment of heart failure patients who are candidates for CRT and 
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will be led by the ‘Research and Innovation’ Committee of the European Association of 
Cardiovascular Imaging (EACVI) and the European Heart Rhythm Association (EHRA). 
The selected centres will be involved in a 12-month inclusion period followed by a 6-
month follow-up period. Institutional ethical approval will be requested in each centre 
according to the local regulations complying with the principles outlined in the 
Declaration of Helsinki for research in human subjects. Patients should be treated 
according to the routine practice of each centre. The implantation of the CRT should not 
be influenced by the data collected. 
Study population 
Inclusion criteria: patients who are listed on clinical grounds for CRT implantation 
according to the current European Society of Cardiology guidelines(6), and will consent 
to the study. They will be evaluated before and 6 months after implantation. Patients 
undergoing upgrades of pacemaker or implantable cardiac defibrillator will also be 
included.  
Exclusion criteria: inappropriate echocardiographic image quality according to the 
judgment of the investigator; absence of echocardiographic follow-up at 6 months; 
absence of an indication for CRT according to the current guidelines; general 
contraindication for CMR (including metallic cerebral clips, non-MR conditional devices) 
and severe renal dysfunction (eGFR<30 ml/min/1.73m2). Patients in atrial fibrillation will 
also be excluded. 
Protocol (Figure 1): The baseline evaluation includes clinical evaluation (NYHA 
functional class, 6-minute walking distance and quality of life), laboratory testing (with 
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specific focus on NT-pro brain natriuretic peptide determination), electrocardiographic 
(ECG) recording, echocardiographic and CMR evaluation of cardiac dimensions and 
function. These investigations will be repeated at 6 months’ follow-up. CMR will be 
repeated at 6 months in patients receiving a CMR-conditional or compatible device. 
Clinical information including cardiovascular risk factors, ECG and biological marker 
(creatinine, haemoglobin, sodium, NT-proBNP) will be collected (Table 1). The ECG will 
be analysed and rhythm, PR interval duration, QRS axis, duration and morphology will 
be recorded according to guidelines (26). 
Before implantation of the CRT device, patients will be imaged by transthoracic 
echocardiography according to a predefined acquisition protocol (Table 2) (27, 28) using 
the same ultrasound platform (ViVid E9, S70 or E95, General Electric Healthcare, 
Horten, Norway). During echocardiography, the ECG-trace recording will be carefully 
optimized to ensure good visualization of the QRS onset throughout the 
echocardiographic assessment. The frame rate of the images should be 50-90 Hz. The 
image quality should be optimized to get the best visualization of the endocardial and 
epicardial borders. At least 3 cardiac cycles will be acquired. In addition to conventional 
grey scale images, contrast agents for cavity opacification will be allowed when needed 
to obtain optimal determination of LV volumes and LVEF. Echocardiography will be 
interpreted on site, the exam will be centralized using a web-platform (ASCENT: 
automated anonymization, and the same recording parameters with a specific password 
for each co-investigator), and a centralized analysis (Inserm 1414 Clinical Investigation 
Center, Innovative Technology, Rennes, F-35000) will be performed. 
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CMR will be performed before device implantation using standard CMR scanners (1.5 
and 3T) with cardiac software. In patients who undergo implantation of an MR-
conditional CRT device, CMR will be repeated at 6-month post-implantation. All CMR 
studies will be performed according to a predefined CMR acquisition protocol detailed 
below, and all anonymized data will be sent and analysed by the Bristol CMR Unit core-
lab. Images will be analysed by an expert operator ESC CMR level III certified using a 
commercially available software (CMR42, Circle Cardiovascular Imaging, Calgary, 
Canada).   
CRT-procedure will be performed as per local standard operating procedures. The post-
implant period will be managed according to the local procedures in each centre. 
Study end-points. At 12 -month, the primary endpoint will be a reduction in left 
ventricular end-systolic volume of ≥15% (i.e. LV reverse remodelling).  
The secondary endpoint will be will be the heart failure clinical composite response (29, 
30). The composite endpoint was developed by Milton Packer(29) at 12-month, This is a 
combined endpoint (QoL, NYHA-class, hospitalization for heart failure and death) that 
has been extensively been used(31). 
Furthermore, event rates for death, hospitalisation for any cardiovascular reason and the 
clinical improvement (as assessed with the  NYHA functional class, the 6 minutes 
walking test distance and the improvement in quality of life according to questionnaires 
used in the Milton Packer score) (29) will be recorded. 
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Echocardiographic data analysis 
A complete echocardiography including Global longitudinal strain (GLS) will be performed 
and recorded for a core laboratory analysis. Left atrial (LA) volume, right ventricular (RV) 
size and function will be recorded according to recommendation (including RV strain free 
wall) (27, 32) 
Assessment of dyssynchrony 
Mechanical dyssynchrony will be quantified using a multi-parametric approach (table 2).  
Intra-ventricular dyssynchrony will be defined by: the presence of septal flash (33) and/or 
apical rocking (34). These two parameters have been previously described and will be 
assessed qualitatively(34, 35). Septal flash is a premature and short contraction of the 
septum during the QRS and then before the aortic valve opening. Apical rocking is a 
displacement or the LV-apex towards the lateral wall. 
Systolic mechanical dispersion will be quantified according to the methodology previously 
proposed(36).    
In addition to these 2 approaches, Mitral inflow pattern, Mitral inflow duration will be 
measured(37). The pattern of LV-septum deformation will be analyzed according to 
Marechaux et al(38). 
Quantification of cardiac work  
Cardiac work will be calculated as a function of time throughout the cardiac cycle from 
the time-strain curve recordings and the estimated LV pressure. Peak systolic LV 
pressure will be assumed to be equal to peak arterial pressure measured with cuff 
manometer, as the average of three recordings. Cardiac work will be assessed by 
calculating the rate of segmental shortening (strain rate) by differentiation of the strain 
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curve and multiplying this with instantaneous LV-pressure. This product is a measure of 
instantaneous power, which will be integrated over time to give work as a function of 
time in systole, defined as the time interval from mitral valve closure to mitral valve 
opening. Two-dimensional imaging of mitral and aortic valves in parasternal long-axis 
(PLAX) view will be used to define timing of opening and closure of the mitral and aortic 
valves(16, 20, 39, 40). 
During the LV ejection period, work performed during segmental elongation represents 
energy loss, defined as negative work (NegW). Work performed during segmental 
shortening represented positive work (PosW). During isovolumetric relaxation, this is 
reversed so that work during shortening is considered negative work and work during 
lengthening is considered positive work. Work efficiency (WE) is defined as PosW / 
(PosW + NegW) x 100. Global positive, negative and work efficiency will be reported as 
the mean values of all LV segments (figure 2).  
Cardiac Magnetic Resonance Imaging (Figure 3) 
The CMR protocol includes standard long- axis views (3-, 2- and 4-chamber views) 
followed by a full stack of continuous short-axis cine encompassing the LV/RV from 
base to apex using a breath-hold steady-state free precession (SSFP) cine technique.  
LGE-CMR imaging will be performed in the same short- and long-axis cine orientation 10-
15 min after administration of 0.1 to 0.2 mmol/kg of gadolinium-chelate contrast agent. 
Images will be acquired using an inversion recovery prepared breath-hold gradient-echo 
technique (IR-GRE) following a Lock-Locker TI shout sequence for the identification of the 
optimal starting TI value to null the signal in the normal myocardium. The inversion time 
will be progressively optimized to null normal myocardium (typical values, 250–350 ms). 
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Each slice will be obtained during a breath-hold of 10 to 15s depending on the patient’s 
heart rate. 
The parameters measured will be LV and RV volumes and ejection fraction. LV fibrosis 
will be measured using the full-width-half-maximum (FWHM) method of the tissue 
characterization module, and expressed both in grams and in % of the LV mass, as 
previously described(41). The location and numbers of myocardial segments affected by 
LGE will be recorded; the transmural extent of LGE will visually assessed per segment 
using a 0-4 score (0=no LGE, 1=0-25% LGE, 2=26-50% LGE, 3= 51-75% LGE, 4=≥75% 
LGE) and quantify also.    
LV global longitudinal strain (GLS) will be measured from two long-axis cine images 
using feature-tracking analyses module.  
Statistical analysis 
The baseline demographic, clinical, echocardiographic and CMR characteristics will be 
compared between patients who have met the primary end-point and those remaining free 
from end-points at 12-month. Similar comparison and description will be performed 
according to secondary end-points. 
After the normality of the distribution is assessed using the Kolmogorov-Smirnov test, all 
baseline continuous variables will be compared between the 2 groups for statistically 
significant differences using Student’s t-test or the Mann-Whitney test, as appropriate. 
Categorical variables will be compared using the Chi² test or Fisher’s exact test. The 
independent determinant of CRT response will be assessed using logistic regression. 
Firstly, univariate analyses will be performed, and odds ratios and 95% of confidence 
EuroCRT   11 
intervals (CI) will be reported. Secondly, all univariate variables with a p-value <0.10 will 
be included in a backward stepwise model. Special care will be maintained to avoid 
collinearity among the included variables. In this regard, variables with a high degree of 
collinearity will be selected according to the best univariate p value. Final variables 
identified as independently associated with the CRT-response will be confronted to the 
previously established predictive score (i.e., the Bernard et al. score(42)). According to 
the current literature and our experience, we anticipate including up to 6 variables (with 
low collinearity) from the dyssynchrony analysis and CMR parameters in the logistic 
regression model aiming to identify the independent determinants of non-response. 
From the literature, the expected response rate to CRT is 70%. According to the main 
secondary endpoint (reduction in LVESV of at least 15%) the rate response is 50% in the 
SEPTAL CRT trial, resulting in 50 to 40% of patients potentially non-responders, 
according to the LV reverse remodelling criteria (43). Consequently, using a ratio of 10 
non-responders for each selected variable, a minimal number of 70 non-responders are 
needed to appropriately answer the primary objective of the observational study. This 
results in a calculated total sample size of 234 for an expected non-response rate of 30%. 
We aim to recruit 250 patients to account for missing data or loss of follow-up.  
 
Discussion 
Imaging modalities have been tested previously and have not met the clinical 
expectations in improving the selection of candidates for CRT(8, 44, 45). Nevertheless, 
new evidence on the role of imaging to select patients for CRT is encouraging (34, 46-
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48). In particular, modern multi-modality imaging approaches have the potential to 
improve the selection of candidates for CRT (Table 4). From previous studies(21, 25), it 
has been shown that the presence of myocardial scar is an important determinant of 
response to CRT. However, its integration in a multi-parametric approach to select 
patients for CRT has not been evaluated in large prospective multi-centre studies using 
dedicated core labs for ultrasound and CMR studies. 
By using echocardiography, new approaches for quantifying the mechanical 
dyssynchrony have been proposed (33). There are also issues that are not completely 
resolved like the relevance of right ventricular function, of secondary mitral regurgitation 
or left atrial size(49-51). Mechanical dispersion is also something that remains to be 
explored in a large series of patients treated by CRT(36). Mechanical dyssynchrony 
parameters can nowadays be quite automatically computed and are taking advantage of 
the past studies and a better understanding of the pathophysiology(52). The strain delay 
index has been proposed and tested in the multicentre MUSIC-trial involving 235 
patients treated by CRT. The results were clearly encouraging (12). There are important 
results published with the cardiac work indices obtained by computing longitudinal strain 
curves(53). In EuroCRT, we will consider an approach combining the timing and the 
amount of segmental deformation using the cardiac work indices previously described 
(16, 20). In addition, the septal flash and apical rocking are two semi-quantitative 
approaches that are easy to apply and to test (33, 54, 55). These simple approaches 
have been tested and validated in some studies but their relative value with respect to 
the quantitative assessment of the cardiac wasted work has not been tested in any large 
multicentre study. It has been decided to use only one sort of echo-machine to increase 
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to robustness. In addition, the centralized reviewing of the images will be extremely 
useful to assess the relative reproducibility of the “automatically” calculated parameters 
extracted from strain curves against the variability of the septal flash and the apical 
rocking (ie comparing corelab versus individual labs involved in EuroCRT)(34).  
Conclusion 
EuroCRT will be the first large multi-centre European prospective observational 
international study to test the role of CMR and modern echocardiographic-updated 
parameters to predict the response to CRT among patients implanted according to the 
current guidelines.  
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Figures legend 
Figure 1: global presentation of the observational study  
Figure 2: presentation of the impact of mechanical dyssynchrony on longitudinal strain 
curves: in blue: the septum with a too early contraction; in red the lateral wall with a 
delayed contraction. 
GLS: global longitudinal strain; TTP: time to peak; WE: wasted energy  
Figure 3: example of the quantification of the late gadolinium enhancement 
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Table 1: Clinical parameters to be recorded 
Parameters Before implantation 6-month follow-up 
Age + + 
Body mass index + + 
Systolic blood pressure + + 
Diastolic blood pressure + + 
Heart rate + + 
NYHA-class + + 
6-minute walk test distance + + 
Creatinine (micromole/l) + + 
Haemoglobin (g/dl) + + 
NT-proBNP (pg/ml) + + 
ACEI/Sartan-dosage/day + + 
Beta-blocker dosage/day + + 
Diuretic dosage/day + + 
MRA dosage/day + + 
Ischaemicaetiology (Y/N) + + 
Heart failure 
decompensation(Y/N before 
implant and during the 6-months 
of follow-up) 
+ + 
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Table 2: Echocardiographic parameters or loops that will be mandatory for the analysis 
or corelab analysis 
Parameters /loops Before implantation 6-month follow-up 
Apical 4-, 2-, 3-ch.views 
showing LV and LA (3 
beats) 
+ + 
Apical 4-, 2-, 3-ch.view with 
colour Doppler on valves 
+ + 
Dedicated loops on the RV 
in 4-ch.view 
+ + 
Mitral inflow (E, A, E-DT) + + 
LVOT VTI (cm) + + 
e’ (septal & lateral) (cm/s) + + 
s’ (septal & lateral) (cm/s) + + 
TR velocity (m/s) + + 
RVs’ (cm/s) + + 
LV EF (%) + + 
GLS (%) + + 
LVEDD (mm)(parasternal 
long-axis view) 
+ + 
LVESD (mm)(parasternal 
long axis view) 
+ + 
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IVS and PW thickness 
(mm) (parasternal long-axis 
view 
+ + 
Parasternal long-axis view 
loop (3 beats) 
+ + 
Parsternal short-axis view 
at the level of papillary 
muscle 
+ + 
RV outflow tract VTI(cm) + + 
Inferior vena cava loops (3 
beats) 
+ + 
Optional: 4D volumetric 
acquisition of the LV over 4 
to 6 beats 
+ + 
Apical 4-Ch. View colour 
DTI highest frame rate loop 
(> 2 beats) 
+ + 
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Table 3: Key imaging parameters that will be examined for their ability to predict the 
response to CRT 
Parameters /loops Before implantation 6-month follow-up 
Localization: amount of LGE +  
LV volumes and diameters + + 
Septal flash + + 
Apical rocking + + 
Pattern of LV longitudinal 
strain(38) 
+ + 
Cardiac work indices + + 
Strain delay indices (cardiac 
work, dispersion,) 
+ + 
LA volumes and deformations + + 
Right ventricular function 
indices (TAPSE) 
+ + 
LV Mechanical dispersion + + 
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Table 4 
 PROSPECT 10 RethinQ26 Echo CRT 27 Euro-CRT 
objectives 
Population 286 out of 498 
enrolled 
80 out of 172 
enrolled 
809 out of 1680 250 
LVEF (%) 23.6 ± 7.0 26 ± 6 27.0 ± 5.4 ≤ 35% 
QRS-duration (ms) 163 ± 22 106± 13 105 ± 12 >120 
Follow-up 
(months) 
6 6 19.4 6 
LV end-diastolic Volume 230 ± 99 
ml 
Volume 210 ± 75 
ml 
Diameter 66.1 ± 
7.4 mm 
unknown 
Use of time to 
peak indices in 
tissue Doppler 
imaging 
+ + - - 
Use of longitudinal 
strain 
- - - + 
Use of patterns of 
LV-regional 
function and 
dyssynchrony 
- - - + 
Use of indices of 
regional LV 
myocardial 
function 
- - - + 
Use of radial strain - - + + 
Use of M-mode + + - + 
Use of pulse 
Doppler indices of 
dyssynchrony 
+ + - + 
 Use of any 
parameter of right 
ventricular 
function or 
pressure 
- - - + 
Use of CMR - - - + 
Result in term of 
interest of imaging 
indices 
- - - unknown 
 
